Stichting Katholieke Universiteit

Chiralix B.v.

Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

Modiquest B.v.

Khondiron IP B.v.

Khondrion IP B.v.

Academisch Ziekenhuis Leiden (h.o.d.n. Leids Universitair Medisch Centrum)

Richard Hendrik Blaauw

Waander Laurens Van Heerde

Geert Jan Sterk

Jan Wouter Drijfhout

Jozef Maria Hendrik Raats

Ruben Gerardus George Leenders

Pedro Harold Han Hermkens

Floris Petrus Johannes Theodorus Rutjes

Gerardus Jozef Maria Pruijn

The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.

Chemiluminescence-based haemostasis assay

The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.

The invention relates to novel compounds that are useful for modulating mitochondrial morphology and/or expression of OXPHOS enzymes and/or cellular ROS. The compounds are derivatives of TroloxrM wherein the carboxylic acid moiety is replaced by an amide moiety and wherein the nitrogen atom of the amide moiety is connected via a linker to a cationic nitrogen atom. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing mitochondrial disorders, conditions associated with mitochondrial dysfunction, including adverse drug effects, and/or neoplastic diseases. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications. 

Chromanyl derivatives for treating mitochondrial disease

The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.

Peptidylarginine deiminase (PAD) inhibitors

Growing community of inventors

Nijmegen, Netherlands

Richard Hendrik Blaauw